Triheptanoin is a fatty acid metabolic modulator. Triheptanoin is potentially used for the treatment of fatty acid oxidation disorders and GLUT1.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Triheptanoin Mitigates Brain ATP Depletion and Mitochondrial Dysfunction in a Mouse Model of Alzheimer's Disease
Xiaodong Yuan, et al. J Alzheimers Dis. 2020;78(1):425-437. PMID: 33016909.
Therapeutic potential of triheptanoin in metabolic and neurodegenerative diseases
Zeinab Wehbe, et al. J Inherit Metab Dis. 2020 May;43(3):385-391. PMID: 31778232.
Triheptanoin protects against status epilepticus-induced hippocampal mitochondrial dysfunctions, oxidative stress and neuronal degeneration
Kah Ni Tan, et al. J Neurochem. 2018 Feb;144(4):431-442. PMID: 29222946.
|Related FAS Products|
TVB-3664 is a FASN inhibitor which significantly reduces tubulin palmitoylation and mRNA expression.
GLPG0974 is a potent and selective FFA2 (also called GPR43) antagonist.
Rimiducid (AP1903) is a lipid-permeable tacrolimus analogue acts by cross-linking the FKBP domains.
Fatostatin A is a cell permeable inhibitor of SREBP activation, it inhibits cancer cell proliferation by affecting mitotic microtubule spindle assembly and cell division.
C75 trans is an enantiomer of C75, which is a synthetic fatty-acid synthase (FASN) inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.